Literature DB >> 11187919

Long-term results of treatment studies for childhood acute lymphoblastic leukemia: Pediatric Oncology Group studies from 1986-1994.

K W Maloney1, J J Shuster, S Murphy, J Pullen, B A Camitta.   

Abstract

This paper presents the long-term results of treatment for children with acute lymphoblastic leukemia (ALL) as conducted by the Pediatric Oncology Group (POG) from 1986 to 1994. The data are presented using standard NCI/Rome risk criteria. The overall event-free survival (EFS) at 5 and 10 years were 70.9% and 67.3% for children with B-precursor ALL, 51.0% and 50.2% for patients with T cell ALL, and 22.4% and 20.9% for infants with ALL. Concomitant biologic studies found that in B-precursor ALL a DNA index (DI) of > or =1.16 and trisomies of both chromosomes 4 and 10 were good prognostic indicators for patients with B-precursor ALL. The traditional prognostic indicators (age and white count), DI and trisomies did not predict outcome in patients with T cell disease. Infants continued to do poorly overall despite more intensive therapy with rotating pairs of chemotherapy. We recommend continued reporting of study results using common risk criteria in order to facilitate comparisons both within and across study groups.

Entities:  

Mesh:

Year:  2000        PMID: 11187919     DOI: 10.1038/sj.leu.2401965

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  11 in total

Review 1.  International collaboration on childhood leukemia.

Authors:  Ching-Hon Pui; Raul C Ribeiro
Journal:  Int J Hematol       Date:  2003-12       Impact factor: 2.490

2.  Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group study AALL0031.

Authors:  K R Schultz; A Carroll; N A Heerema; W P Bowman; A Aledo; W B Slayton; H Sather; M Devidas; H W Zheng; S M Davies; P S Gaynon; M Trigg; R Rutledge; D Jorstad; N Winick; M J Borowitz; S P Hunger; W L Carroll; B Camitta
Journal:  Leukemia       Date:  2014-01-20       Impact factor: 11.528

3.  Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children's Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the Children's Oncology Group.

Authors:  Yousif Matloub; Susan Lindemulder; Paul S Gaynon; Harland Sather; Mei La; Emmett Broxson; Rochelle Yanofsky; Raymond Hutchinson; Nyla A Heerema; James Nachman; Marilyn Blake; Linda M Wells; April D Sorrell; Margaret Masterson; John F Kelleher; Linda C Stork
Journal:  Blood       Date:  2006-04-11       Impact factor: 22.113

4.  Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG).

Authors:  Kirk R Schultz; D Jeanette Pullen; Harland N Sather; Jonathan J Shuster; Meenakshi Devidas; Michael J Borowitz; Andrew J Carroll; Nyla A Heerema; Jeffrey E Rubnitz; Mignon L Loh; Elizabeth A Raetz; Naomi J Winick; Stephen P Hunger; William L Carroll; Paul S Gaynon; Bruce M Camitta
Journal:  Blood       Date:  2006-09-26       Impact factor: 22.113

Review 5.  Acute leukemia as a secondary malignancy in children and adolescents: current findings and issues.

Authors:  Nobuko Hijiya; Kirsten K Ness; Raul C Ribeiro; Melissa M Hudson
Journal:  Cancer       Date:  2009-01-01       Impact factor: 6.860

6.  Adults with acute lymphoblastic leukemia and translocation (1;19) abnormality have a favorable outcome with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with methotrexate and high-dose cytarabine chemotherapy.

Authors:  Ravin Garg; Hagop Kantarjian; Deborah Thomas; Stefan Faderl; Farhad Ravandi; Denise Lovshe; Sherry Pierce; Susan O'Brien
Journal:  Cancer       Date:  2009-05-15       Impact factor: 6.860

7.  Risk factors for symptomatic osteonecrosis in childhood ALL: A retrospective study of a Slovenian pediatric ALL population between 1970 and 2004.

Authors:  Nataša Karas-Kuželički; Simona Mencej-Bedrač; Janez Jazbec; Janja Marc; Irena Mlinarič-Raščan
Journal:  Exp Ther Med       Date:  2016-05-25       Impact factor: 2.447

8.  Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study.

Authors:  Kirk R Schultz; W Paul Bowman; Alexander Aledo; William B Slayton; Harland Sather; Meenakshi Devidas; Chenguang Wang; Stella M Davies; Paul S Gaynon; Michael Trigg; Robert Rutledge; Laura Burden; Dean Jorstad; Andrew Carroll; Nyla A Heerema; Naomi Winick; Michael J Borowitz; Stephen P Hunger; William L Carroll; Bruce Camitta
Journal:  J Clin Oncol       Date:  2009-10-05       Impact factor: 44.544

9.  Acute lymphoblastic leukemia in children: correlation of musculoskeletal manifestations and immunophenotypes.

Authors:  Eran Maman; David M Steinberg; Batia Stark; Shai Izraeli; Shlomo Wientroub
Journal:  J Child Orthop       Date:  2007-02-23       Impact factor: 1.548

10.  Translating microarray data for diagnostic testing in childhood leukaemia.

Authors:  Katrin Hoffmann; Martin J Firth; Alex H Beesley; Nicholas H de Klerk; Ursula R Kees
Journal:  BMC Cancer       Date:  2006-09-26       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.